Corebridge Q3 Call: $100M of Merger Synergies Identified, Year-End Close Targeted
CRBG sits 61% above its 52-week low of $22.19 on elevated volume (1.8× avg).
Summary
Corebridge's Q3 call transcript adds merger detail beyond the already-reported results: over $100 million of run-rate expense savings identified, more than $1.5 billion of PRT deals set to close in Q4, and a year-end merger close still targeted.
Key Events · Earnings and Guidance · CRBG
-
Q3 Operating EPS $1.22, Up 27%
Operating EPS rose 27% year-over-year to $1.22, a penny below the $1.24 consensus, while revenue fell 20% to $4.50 billion. Adjusted ROE was 12.1%, or 13.4% on a run-rate basis.
-
Over $100M of Merger Synergies Identified
Management has identified over $100 million of run-rate expense savings to be realized in the first half of 2027, toward a $150 million 2027 target and at least $500 million by the end of 2028.
-
$1.5B of PRT Deals Set for Q4
Q3 PRT volume was modest at $156 million, but Corebridge has already been selected as counterparty on over $1.5 billion of PRT transactions expected to close in the fourth quarter.
-
Year-End Merger Close Targeted
All required federal approvals for the Equitable merger are received; state and international approvals remain outstanding, with the company still guiding to a year-end close and new Board members already selected.
Analysis · CRBG · Finance
With the Q3 numbers already out on November 2, the transcript's value lies in the forward detail. Management has identified over $100 million of run-rate expense savings to be realized in the first half of 2027, putting the company on the way to a $150 million 2027 target and at least $500 million by the end of 2028. It also disclosed that it has been selected as counterparty on more than $1.5 billion of pension risk transfer deals expected to close in the fourth quarter, following a soft $156 million of PRT volume in Q3. All federal approvals for the Equitable merger are in hand, with state and international approvals still pending and a year-end close still the target. Against that, Q3 operating EPS of $1.22 missed the $1.24 consensus by a penny and revenue fell 20% to $4.50 billion, so the quarter itself was not a beat.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBG was trading at $35.75 on NYSE in the Finance sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $22.19 to $36.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.